Table 3.
Disease characteristics by plasma concentration quintiles (1, 3 and 5) of adiponectin (or leptin) among prostate cancer (PCa) cases a
| Characteristic | Quintile 1 | Quintile 3 | Quintile 5 | P c |
|---|---|---|---|---|
| Adiponectin (mg/L), median (range) | 2.7 (0.2-3.8) | 6.3 (5.5-7.2) | 13.3 (10.5-26.3) | -- |
| N | 133 | 118 | 100 | -- |
| Metastases or PCa-specific death by 2007, N (%) |
28 (21.1) | 20 (17.0) | 9 (9.0) | 0.13 |
| BMI (kg/m2) b | 25.3 ± 2.5 | 24.7 ± 2.7 | 24.1 ± 2.3 | <0.0001 |
| Baseline PSA (ng/mL), median (10th–90th percentile) |
2.7 (1.0-14.4) | 2.5 (0.8-13.0) | 2.5 (0.8-8.6) | 0.37 |
| PSA at diagnosis (ng/mL), median (10th–90th percentile) |
8.0 (3.5-28.4) | 9.0 (4.1-50.0) | 8.0 (4.0-31.0) | 0.49 |
| Tumor grade at diagnosis d, N (%) | ||||
| Gleason 2-6/well-differentiated | 41 (31.8) | 44 (38.3) | 41 (42.3) | |
| Gleason 7/moderately-differentiated | 61 (47.3) | 50 (43.5) | 38 (39.2) | 0.81 |
| Gleason 8-10/poorly-differentiated | 27 (20.9) | 21 (18.2) | 18 (18.5) | |
| Clinical stage at diagnosis d, N (%) | ||||
| T1/T2N0M0 | 92 (76.0) | 82 (76.6) | 69 (77.5) | |
| T3/T4N0M0 | 24 (19.8) | 16 (15.0) | 17 (19.1) | 0.42 |
| TxN1/M1 | 5 (4.2) | 9 (8.4) | 3 (3.4) | |
|
| ||||
| Leptin (μg/L), median (range) | 2.4 (1.0-3.1) | 5.5 (4.6-6.5) | 13.4 (10.3- 119.2) |
-- |
| N | 125 | 132 | 128 | |
| Metastases and/or died of PCa by 2007, N (%) |
23 (18.4) | 24 (18.2) | 22 (17.2) | 0.83 |
| BMI (kg/m2) b | 23.2 (21.1- 25.1) |
24.3 (22.4- 26.4) |
26.4 (23.5-29.8) | <0.0001 |
| Baseline PSA (ng/mL), median (10th–90th percentile) |
2.5 (0.8-11.5) | 2.5 (0.9-17.6) | 2.4 (1.0-15.3) | 0.80 |
| PSA at diagnosis (ng/mL), median (10th–90th percentile) |
9.6 (3.4-35.4) | 7.5 (3.6-28.0) | 8.4 (4.5-28.9) | 0.28 |
| Tumor grade at diagnosis d, N (%) | ||||
| Gleason 2-6/well-differentiated | 45 (37.2) | 48 (38.1) | 43 (34.4) | |
| Gleason 7/moderately-differentiated | 51 (42.1) | 58 (46.0) | 54 (43.2) | 0.83 |
| Gleason 8-10/poorly-differentiated | 25 (20.7) | 20 (15.9) | 28 (22.4) | |
| Clinical stage at diagnosis d, N (%) | ||||
| T1/T2N0M0 | 86 (76.1) | 89 (73.6) | 90 (77.6) | 0.90 |
| T3/T4N0M0 | 20 (17.7) | 23 (19.0) | 20 (17.2) | |
| TxN1/M1 | 7 (6.2) | 9 (7.4) | 6 (5.2) | |
a
Quintile categories was defined based on the distribution among controls.
b
Mean ± standard deviation.
c
P-values calculated using generalized linear regression for BMI and nonparametric techniques for plasma concentrations of PSA at baseline and at diagnosis.
d
American Joint Committee on Cancer (AJCC) TNM classification system. Cases with unknown clinical stage (or grade/Gleason score) were excluded.